CMS: Rethinking Competitive Bidding Models
- This analysis examines the Centers for Medicare & Medicaid Services (CMS) competitive bidding system for Durable Medical Equipment (DME),its history,current issues,and potential future.
- What: CMS is expanding its competitive bidding program for DME too include urology, tracheostomy, and ostomy supplies, building on a system initially implemented in 2011.
- Where: The program impacts beneficiaries nationwide who rely on DME covered by Medicare.
CMS Competitive Bidding for DME: A Deep Dive
This analysis examines the Centers for Medicare & Medicaid Services (CMS) competitive bidding system for Durable Medical Equipment (DME),its history,current issues,and potential future.
What: CMS is expanding its competitive bidding program for DME too include urology, tracheostomy, and ostomy supplies, building on a system initially implemented in 2011. This system aims to lower costs for Medicare by awarding contracts to DME suppliers based on bids. Tho, the current system and proposed expansion are facing criticism for potentially compromising patient care and access.
Where: The program impacts beneficiaries nationwide who rely on DME covered by Medicare. The bidding process is managed centrally by CMS, with contracts awarded to suppliers operating in designated Competitive Bid Areas (CBAs).
When:
* 2011: CMS implemented the current competitive bidding system, replacing a failed fixed-fee schedule.
* 2021: Round 2021 of competitive bidding failed to meet savings goals,leading to a two-year gap period where CMS reverted to the fee schedule.
* 2025 (proposed): CMS plans to relaunch the program with changes, expanding it to include urology, tracheostomy, and ostomy supplies.
Why it Matters: The DME market is crucial for patients needing medical equipment to maintain independence and avoid costly institutional care. A flawed bidding system can lead to:
* Reduced Quality of Care: Bidding incentivizes lower costs, potentially resulting in suppliers offering lower-quality equipment.
* Access issues: Supplier attrition (companies dropping out) can leave beneficiaries with limited or no access to necessary supplies.
* Financial Strain: while aiming for savings, the system can create instability in the DME market, potentially impacting supplier viability.
* Inefficient Spending: Past failures demonstrate the system doesn’t consistently achieve its intended cost savings.
Ancient Context & System Flaws:
The current system arose from the failure of a fixed-fee schedule in compensating DME suppliers. The General Accounting Office (GAO) and the Inspector General of the Department of Health and Human Services criticized the fixed-fee approach as wasteful and illogical. CMS then adopted a competitive bidding system, but it contained a unique and problematic feature:
* Median-Based Pricing: CMS sets the winning bid equal to the median price of all winning bidders. This is a “never before seen” approach that creates adverse incentives. It doesn’t necessarily reflect the true cost of providing quality DME and can drive down prices to unsustainable levels.
Data on Past Bidding Rounds:
| Round | Year | Areas Affected | Supplier Attrition | Savings Achieved? | Outcome |
|---|---|---|---|---|---|
| Round 1 | 2013 | 9 CBAs | Significant | Yes | mixed results, some access concerns |
| Round 2 | 2016 | 30 CBAs | high | Yes | Increased access gaps, supplier complaints |
| 2021 | 2021 | Nationwide | Very High | No | Gap period, reversion to fee schedule |
Source: compiled from information in the provided text and publicly available CMS data.
Current Concerns & Proposed Changes:
CMS is attempting to address the flaws of the previous system in the relaunch.Though, concerns remain, especially regarding the expansion to new supply categories.The proposed rule changes are being scrutinized by industry stakeholders (like VGM) who highlight potential challenges.
What’s Next:
* Continued Stakeholder Feedback: CMS is accepting comments on the proposed rule, allowing for input from suppliers, patient advocacy groups, and othre interested parties.
* Program Relaunch (2025): CMS intends to relaunch the competitive bidding program, incorporating changes based on feedback.
* Monitoring & Evaluation: Close monitoring of the program’s impact on patient access, quality of care, and cost savings will be crucial. Further adjustments may be necessary.
* Potential Legislative Action: If the program continues to demonstrate significant flaws, legislative intervention may be considered to reform the DME payment system.